ReviewFrontiers in physiology2017
The Total Artificial Heart in End-Stage Congenital Heart Disease.
Review in Frontiers in physiology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 26 citations in OpenAlex.
- A compact machine perfusion device for whole blood perfusion in isolated rat liver.Journal of artificial organs : the official journal of the Japanese Society for Artificial Organs · 2025Article
- Editorial: Physiology in extreme conditions: Adaptations and unexpected reactions, Volume II.Frontiers in physiology · 2023Article
- Mechanical circulatory support devices and treatment strategies for right heart failure.Frontiers in cardiovascular medicine · 2022Review
- Biventricular assist devices and total artificial heart: Strategies and outcomes.Frontiers in cardiovascular medicine · 2022Review
- The total artificial heart in patients with congenital heart disease.Annals of cardiothoracic surgery · 2020Article
- Current Role of the Total Artificial Heart in the Management of Advanced Heart Failure.Current cardiology reports · 2019Review
- Mechanical circulatory support in children: past, present and future.Translational pediatrics · 2019Review
- Cardiac Assist Devices: Early Concepts, Current Technologies, and Future Innovations.Bioengineering (Basel, Switzerland) · 2019Review
- Extracorporeal Membrane Oxygenation (ECMO) Support in Special Patient Populations-The Bidirectional Glenn and Fontan Circulations.Frontiers in pediatrics · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The development of durable ventricular assist devices (VADs) has improved mortality rates and quality of life in patients with end stage heart failure. While the use of VADs has increased dramatically in recent years, there is limited experience with VAD implantation in patients with complex congenital heart disease (CHD), despite the fact that the number of patients with end stage CHD has grown due to improvements in surgical and medical care. VAD use has been limited in patients with CHD and end stage heart failure due to anatomic (systemic right ventricle, single ventricle, surgically altered anatomy, valve dysfunction, etc.) and physiologic constraints (diastolic dysfunction). The total artificial heart (TAH), which has right and left sided pumps that can be arranged in a variety of orientations, can accommodate the anatomic variation present in CHD patients. This review provides an overview of the potential use of the TAH in patients with CHD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.